Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2016-07-14 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
PHARMING Amends RUCONEST Distribution Agreement with SOBI
Regulatory Filings Classification · 95% confidence The document is a press release dated July 14, 2016, announcing an amendment to a distribution agreement for the drug RUCONEST®. It details changes in commercialization rights and market expansion. This type of announcement, which concerns business operations, partnerships, and strategic changes rather than routine financial reporting (like 10-K, ER, or IR), typically falls under general corporate news. Since it is not a specific filing like a Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), and it is not a transcript (CT) or a formal presentation (IP), the most appropriate general category for a significant business update that doesn't fit the highly specific financial/regulatory codes is the general Regulatory Filings/Announcements category (RNS), as it is a public disclosure of material business information.
2016-07-14 English
Pharming Reports on Annual General Meeting of Shareholders Pharming's Board of Supervisory Directors Announce Paul Sekhri as New Chairman
AGM Information Classification · 99% confidence The document explicitly states it is reporting on the 'Annual General Meeting of Shareholders' and details outcomes from that meeting, including the approval of all proposals and the announcement of a new Chairman for the Board of Supervisory Directors. The title is 'Pharming Reports on Annual General Meeting of Shareholders'. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions management changes (MANG), the primary context and framing are centered around the AGM event itself.
2016-05-26 English
Pharming Group: Interim Report on Financial Results for Q1 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report on Financial Results for Q1 2016' and contains detailed financial statements, including an income statement, balance sheet, and management commentary on financial performance for the first quarter. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2016
2016-05-18 English
Pharming Group Supports hae day :-) 2016
Environmental & Social Information Classification · 99% confidence The document is a press release dated May 16, 2016, announcing Pharming Group N.V.'s support for the Fifth Annual International Hereditary Angioedema Day (HAE Day). It discusses the disease, the company's product RUCONEST®, and general corporate information. This type of announcement, which is a general corporate update or news release that doesn't fit the specific financial reporting categories (like 10-K, ER, IR, or DIV), falls best under the general 'Regulatory Filings' or 'Miscellaneous' category, which is RNS in this schema, as it is a public announcement of corporate activity/support, often filed with regulators as a general disclosure. It is not a formal financial report, earnings release, or management discussion.
2016-05-16 English
Pharming Announces Adoption by the European Commission of the CHMP Recommendation to Change the Terms of the Marketing Authorisation for Ruconest®
Regulatory Filings Classification · 95% confidence The document is a press release dated April 7, 2016, announcing a regulatory decision by the European Commission regarding the marketing authorization for the drug RUCONEST®. Specifically, it details changes to the label, including approval for use in adolescents and the removal of IgE testing requirements, based on a recommendation from the CHMP. This type of announcement, detailing a specific regulatory or product update that is not a full financial report (like 10-K or IR) or a general earnings release (ER), fits best under the category of general Regulatory Filings (RNS) or potentially a specific product/legal update. Since it is an announcement about a regulatory action concerning a product's approval status, and it doesn't fit the specific definitions for ER, AR, LTR, or CAP, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for this type of corporate news release that isn't a standard financial report or management change.
2016-04-07 English
Annual Report 2015
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2015' and contains comprehensive sections including a CEO statement, management report, corporate governance, and full consolidated financial statements (balance sheet, income statement, cash flows). It is clearly the primary annual reporting document for Pharming Group N.V. for the 2015 fiscal year, not an announcement or summary. FY 2015
2016-03-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.